Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has filed a Registration Statement on Form S-1 with the US Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) of Anteris Technologies Global Corp’s (ATGC) common stock on the US Nasdaq stock exchange.
The stock volume and price range have yet to be determined, and the IPO will be subject to market conditions with no guarantees as to completion, size, price or terms.
The move follows Anteris’ re-domiciliation of its group and subsidiaries to the US. The company now intends to list to the Nasdaq via schemes of arrangement between AVR and AVR shareholders and option holders, under the symbol 'AVR'.
Post Nasdaq offering, the Anteris Group intends to list its CHESS depositary interests (CDIs) on the ASX under the symbol AVR as well.
Developing structural heart devices
Anteris is developing structural heart health devices designed to meet unmet patient need.
The company’s lead product is the DurAVR® transcatheter heart valve (THV) for treating aortic stenosis, designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons.
It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. The biomimetic valve is shaped to mimic the performance of a healthy human aortic valve.
DurAVR® THV is made using ADAPT® tissue, Anteris’ patented anti-calcification tissue technology.
ADAPT® tissue has been used clinically for over 10 years and distributed for use in more than 55,000 patients worldwide.
The company’s patented ComASUR® Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR® THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve optimal valve positioning.